EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes

Alvita Vilkeviciute iD, Dzastina Cebatoriene, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25136859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Alvita Vilkeviciute und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A, Interleukin-10, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research Council of Lithuania under the initiative of Researcher Group Projects., The Research Council of Lithuania under the initiative of Researcher Group Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age-related macular degeneration (AMD) is a progressive neurodegenerative condition leading to vision loss and eventual blindness, with exudative AMD posing a heightened risk due to choroidal neovascularization and localized edema. Therapies targeting the VEGF pathway aim to address this mechanism for treatment effectiveness. Our study aimed to evaluate associations between specific genetic variants (RAD51B rs8017304, rs2588809; TRIB1 rs6987702, rs4351379; COL8A1 rs13095226; COL10A1 rs1064583; IL-9 rs1859430, rs2069870, rs11741137, rs2069885, rs2069884; IL-10 rs1800871, rs1800872, rs1800896; VEGFA rs1570360, rs699947, rs3025033, rs2146323) and the response to anti-VEGF treatment for exudative AMD. We enrolled 119 patients with exudative AMD categorized as responders or non-responders based on their response to anti-VEGF treatment. Statistical analysis revealed that RAD51B rs8017304 heterozygous and homozygous minor allele carriers had increased CMT before treatment compared to wild-type genotype carriers (p = 0.004). Additionally, TRIB1 rs4351379 heterozygous and homozygous minor allele carriers exhibited a greater decrease in central macular thickness (CMT) after 6 months of treatment than wild-type genotype carriers (p = 0.030). IL-9 rs1859430, rs2069870, and rs2069884 heterozygous and homozygous minor allele carriers had worse BCVA before treatment than wild-type genotype carriers (p = 0.018, p = 0.012, p = 0.041, respectively). Conversely, IL-9 rs2069885 heterozygous and homozygous minor allele carriers showed greater improvement in BCVA after 6 months compared to wild-type genotype carriers (p = 0.032). Furthermore, VEGFA rs699947 heterozygous and homozygous minor allele carriers had better BCVA before treatment and after 3 and 6 months of treatment than wild-type genotype carriers (p = 0.003, p = 0.022, respectively), with these carriers also exhibiting higher CMT after 6 months of anti-VEGF treatment (p = 0.032). Not all results remained statistically significant under this stringent correction for multiple comparisons. The comparisons of the serum concentrations of IL-10, VEGF-A, and VEGF-R2/KDR between non-responders and responders did not yield statistically significant differences. Our study identified significant associations between genetic variants, including RAD51B rs8017304, TRIB1 rs4351379, IL-9 rs1859430, rs2069870, rs2069884, rs2069885, and VEGFA rs699947, and parameters related to the efficacy of exudative AMD treatment, such as BCVA and CMT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymorphism, Single NucleotideVascular Endothelial Growth Factor AInterleukin-10Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesInterleukin-9Collagen Type XHumansMaleFemaleAgedTreatment OutcomeMacular DegenerationAged, 80 and overDNA-Binding ProteinsMiddle AgedGenotypeCollagen Type VIII

Stichwörter der Autor:innen

ELISAage-related macular degenerationanti-VEGFA therapysingle-nucleotide variants

Substanzen

Vascular Endothelial Growth Factor AInterleukin-10VEGFA protein, humanIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesInterleukin-9TRIB1 protein, humanCollagen Type XCOL10A1 protein, humanCol8A1 protein, human

Autor:innen und Institutionen

  • Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.
  • Medical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus St. 9, LT-44307 Kaunas, Lithuania.
  • Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu St. 2, LT-50161 Kaunas, Lithuania.

ORCID-Profile: Alvita Vilkeviciute

Förderung

  • The Research Council of Lithuania under the initiative of Researcher Group Projects.
  • The Research Council of Lithuania under the initiative of Researcher Group Projects

Zitieren

APA

Vilkeviciute, A., Cebatoriene, D., Kriauciuniene, L., Zaliuniene, D., & Liutkeviciene, R. (2024). Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136859

Vancouver

Vilkeviciute A, Cebatoriene D, Kriauciuniene L, Zaliuniene D, Liutkeviciene R. Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136859

BibTeX
@article{Vilkeviciute2024,
  author = {Vilkeviciute, Alvita and Cebatoriene, Dzastina and Kriauciuniene, Loresa and Zaliuniene, Dalia and Liutkeviciene, Rasa},
  title = {Exudative Age-Related Macular Degeneration: Association between Treatment Efficacy and Single-Nucleotide Variants in RAD51B, TRIB1, COL8A1, COL10A1, IL-9, IL-10, and VEGFA Genes},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25136859}
}
Kostenlos starten →